Analgesic compositions comprising anti-epileptic compounds...

Drug – bio-affecting and body treating compositions – Preparations characterized by special physical form – Tablets – lozenges – or pills

Reexamination Certificate

Rate now

  [ 0.00 ] – not rated yet Voters 0   Comments 0

Details

C424S451000, C424S489000

Reexamination Certificate

active

06942876

ABSTRACT:
The present invention is directed to novel combinations of anti-epileptic compounds that demonstrate pain alleviating properties, with compounds selected from the group consisting of analgesics, NMDA receptor antagonists, and NSAIDs and pharmaceutical compositions comprising same. It has been discovered that the administration of anti-epileptic compounds that demonstrate pain alleviating properties in these novel combinations results in an improved reduction in the frequency and severity of pain. It is also believed that the incidence of unwanted side effects can be reduced by these novel combinations in comparison to using higher doses of a single agent treatment to achieve a similar therapeutic effect. The present invention is also directed to methods of using effective amounts of the novel pharmaceutical compositions to treat pain in mammals.

REFERENCES:
patent: 4024175 (1977-05-01), Satzinger et al.
patent: 4087544 (1978-05-01), Satzinger et al.
patent: 5234929 (1993-08-01), Chelen
patent: 5321012 (1994-06-01), Mayer et al.
patent: 5352638 (1994-10-01), Beall et al.
patent: 5420270 (1995-05-01), Chandrakumar et al.
patent: 5466823 (1995-11-01), Talley et al.
patent: 5556838 (1996-09-01), Mayer et al.
patent: 5563175 (1996-10-01), Silverman et al.
patent: 6001876 (1999-12-01), Singh
patent: 6057373 (2000-05-01), Fogel et al.
patent: 6127418 (2000-10-01), Bueno et al.
patent: 6187338 (2001-02-01), Caruso et al.
patent: 6197819 (2001-03-01), Silverman et al.
patent: 6242488 (2001-06-01), Bueno et al.
patent: 6406716 (2002-06-01), Caruso et al.
patent: 6426368 (2002-07-01), Bueno et al.
patent: 6451857 (2002-09-01), Hurtt et al.
patent: 6593368 (2003-07-01), Magnus-Miller et al.
patent: 634N102 (1963-12-01), None
patent: 1110141 (1995-10-01), None
patent: 1966802 (1974-04-01), None
patent: 2255279 (1992-11-01), None
patent: 54110334 (1979-08-01), None
patent: 61221121 (1986-10-01), None
patent: 6100468 (1994-04-01), None
patent: 6227969 (1994-08-01), None
patent: 8701036 (1987-02-01), None
patent: WO 87/01036 (1987-02-01), None
patent: 8905642 (1989-06-01), None
patent: WO 89/05642 (1989-06-01), None
patent: WO 93/23383 (1993-11-01), None
patent: 9607412 (1996-03-01), None
patent: 9807447 (1998-02-01), None
patent: WO 98/07447 (1998-02-01), None
patent: WO 99/08670 (1999-02-01), None
patent: WO 99/08671 (1999-02-01), None
Shimoyama et al., “Gabapentin enhances the antinociceptive effects of spinal morphine in the rat tail-flick test”, Pain, vol. 72, 1997, pp. 375-382.
Wetzel et al., “Use of Gabapentin in Pain Management”, The Annals of Pharmacology, vol. 31, 1997, pp. 1082-1083.
Theodore W. Rall, et al., “Drugs Effective in the Therapy of the Epilepsies”, The Pharmacological Basis of Therapeutics, 8th Ed., Editors Alfred Goodman Gilman, MD, Ph.D., Theodore W. Rall, Ph.D., D.Med., Alan S. Nies, MD, and Palmer Taylor, Ph.D., copyright 1990, pp. 436-462, Pergamon Press, NY, NY.
Rosner, et al., “Gabapentin Adjunctive Therapy in Neuropathic Pain States” The Clinical Journal of Pain, 1996;12:56-58.
PCT International Search Report PCT/US98/17083.
Kathryn J. Elliot, “New Analgesics Emerge From Pain Pathogenesis Research”, Oncology News International, Apr. 1997, pp 14-15.
Gary Mellick, et al., “The Use of Gabapentin in the Treatment of Reflex Sympathetic Dystrophy and a Phobic Disorder”, American Journal of Pain Management, vol. 5, No. 1, Jan. 1995, pp 7-9.
Y Miyamoto, et al., “Antinociceptive Synergism Between Supraspinal and Spinal Sites After Subcutaneous Morphine Evidenced by CNS Morphine Content”, Brain Research, 552, 19991, pp 136-140.
Howard Rosner, et al., “Gabapentin Adjunctive Therapy in Neuropathic Pain States”, The Clinical Journal of Pain, vol. 12, No. 1, 1996, pp 56-58.
Steven C. Schachter, et al., “Treatment of Central Pain with Gabapentin Case Reports”, J. Epilepsy, vol. 9, No. 3, 1996, pp 223-224.
Alan Z. Segal, et al., “Gabapentin as a Novel Treatment for Postherpetic Nuralgia”, Neurology, Vo. 46, Apr. 1996, pp 1175-1176.
Megumi Shimoyama, et al., “Gabapentine Enhances the Antiociceptive Effects of Spinal Morphine in the Rat Tail-flick Test”, Pain, vol. 72, 1997, pp 375-382.
Ronald J. Tallarida, et al., Statistical Analysis of Drug-Drug and Site-Site Interactions with Isobolograms, Life Sciences, vol. 45, 1989, pp 947-961.
Ronald J. Tallarida, “Statistical Analysis of Drug Combinations for Synergism”, Pain, vol. 49, 1992, pp 93-97.
Ronald J. Tallarida et al., “Testing for Synergism Over a Range of Fixed Ratio Drug Combinations: Replacing the Isobologram”, Life Sciences, vol. 58, No. 2, 1996, pp 23-28.
John J. Zapp, “Postpoliomyelitis Pain Treated with Gabapentin”, American Family Physician, vol. 53, No. 8, Jun. 1996, pp 2442-2445.
Wetzel, et al, “Use of gabapentin in pain management”, Ann. Pharmacother., 1997; 31(9): pp 1082-1083 CODEN:APHRER; ISSN:1060-0280.
Stanfa, et al, “Gabapentin, ineffective in normal rats, markedly reduces C-Fiber evoked response after inflammation”, NeuroReport, 1997; 8(3); pp 587-590. CODEN:NERPEZ; ISSN:0959-4965.

LandOfFree

Say what you really think

Search LandOfFree.com for the USA inventors and patents. Rate them and share your experience with other people.

Rating

Analgesic compositions comprising anti-epileptic compounds... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Analgesic compositions comprising anti-epileptic compounds..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Analgesic compositions comprising anti-epileptic compounds... will most certainly appreciate the feedback.

Rate now

     

Profile ID: LFUS-PAI-O-3451276

  Search
All data on this website is collected from public sources. Our data reflects the most accurate information available at the time of publication.